Biologic Response Modifiers

The ratio of T-helper cell type 1 (Th1) and type 2 (Th2) has been hypothesized to be critical for disease progression. In advanced stages there is a dominant Th2 cytokine profile leading to an impaired host antitumor response.51 Treatments such as biologic response modifiers target the reconstitution of immune function for disease control. Currently, immune-modifying treatment options such as bexarotene, immunomodulatory cytokines such as interferon-alpha (INF-a), and inter-leukin 2 and 12 (IL-2, IL-12), and extracorporeal pho-topheresis (ECP) are used to treat MF/SS.

0 0

Post a comment